Structure, signaling and the drug discovery of the Ras oncogene protein
- PMID: 28571593
- PMCID: PMC5584742
- DOI: 10.5483/bmbrep.2017.50.7.062
Structure, signaling and the drug discovery of the Ras oncogene protein
Abstract
Mutations in Ras GTPase are among the most common genetic alterations in human cancers. Despite extensive research investigating Ras proteins, their functions still remain a challenge over a long period of time. The currently available data suggests that solving the outstanding issues regarding Ras could lead to development of effective drugs that could have a significant impact on cancer treatment. Developing a better understanding of their biochemical properties or modes of action, along with improvements in their pharmacologic profiles, clinical design and scheduling will enable the development of more effective therapies. [BMB Reports 2017; 50(7): 355-360].
Conflict of interest statement
The authors have no conflicting financial interests.
Figures


References
-
- Victor T, Du Toit R, Jordaan AM, Bester AJ, Van Helden PD. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res. 1990;50:4911–4914. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources